This preview shows pages 1–2. Sign up to view the full content.
This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: Fosamax (alendronate), Evista, Boniva, Goal: Prevention or treatment of osteoporosis Safe dose & range: PO (Adults): Treatment of osteoporosis -- 10 mg once daily or 70 mg once weekly. Prevention of osteoporosis-- 5 mg once daily or 35 mg once weekly. Paget's disease-- 40 mg once daily for 6 mo. Re-treatment may be considered for patients who relapse. Treatment of corticosteroid-induced osteoporosis in men and premenopausal women-- 5 mg once daily. Treatment of corticosteroid-induced osteoporosis in postmenopausal women not receiving estrogen-- 10 mg once daily. Classification, Action & Indication: C- Therapeutic: bone resorption inhibitors Pharmacologic: biphosphonates A- Inhibits resorption of bone by inhibiting osteoclast activity. Therapeutic Effects: Reversal of the progression of osteoporosis with decreased fractures. Decreased progression of Paget's disease. I- Treatment and prevention of postmenopausal osteoporosis. Treatment of osteoporosis in men. Treatment of Paget's disease of the bone. Treatment of corticosteroid-induced osteoporosis in patients (men and women) who are receiving ≥7.5 mg of prednisone/day (or equivalent) with evidence of decreased bone mineral density.prednisone/day (or equivalent) with evidence of decreased bone mineral density....
View Full Document
This note was uploaded on 11/08/2010 for the course NUR 2000 taught by Professor Rn during the Spring '10 term at Florida State College.
- Spring '10